Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINIUS: Guselkumab and transmural healing in ulcerative colitis
jRCT1031250537Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Primary endpoint: Complete transmural healing at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1031250537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250537.